Research programme: dioxygenase inhibitors - NewLink GeneticsAlternative Names: Ethyl pyruvate - NewLink Genetics; Indoleamine-2,3-dioxygenase (IDO) pathway inhibitors - NewLink Genetics; NLG-802; Tryptophan-2,3-dioxygenase inhibitors - NewLink Genetics
Latest Information Update: 22 Oct 2014
At a glance
- Originator Lankenau Institute for Medical Research
- Developer Genentech; Lankenau Institute for Medical Research; NewLink Genetics Corporation
- Class Small molecules
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
- Discontinued Hepatitis C; HIV infections